Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03694093 · ClinicalTrials.gov registry record
Assessing the Effect of Patient Characteristics on Treatment Response in Primary Hyperhidrosis
A clinical trial, sponsored by St. Louis University.
- Completed
- Registry status
- 41
- Enrollment target
NCT03694093: Completed study, sponsored by St. Louis University.
NCT03694093 is a clinical trial that has completed, run by St. Louis University. The registered enrollment target is 41 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03694093 has completed, sponsored by St. Louis University.
- COMPLETED
- Registry status
- 41 participants
- Enrollment target
Study Summary
This study will describe the treatment of hyperhidrosis (excessive sweating) in clinical practice and explore the effect of patient characteristics on treatment response. This study will follow 200 people with hyperhidrosis over 18 months. Anyone with primary hyperhidrosis (excessive sweating not due to another medical condition) over the age of 12 may participate. Study participants will have multiple office visits during which they will asked to rate the severity of their sweat production in multiple areas (i.e. underarms, hands, feet), answer a questionnaire regarding their disease and treatment, and undergo a non-invasive measurement of sweat production called gravimetry. Gravimetry is performed by placing absorbent material in an area, such as the underarms, for a set amount of time and then measuring the amount of sweat collected. In between clinic visits, study participants will be contacted electronically to answer several questions regarding their disease and treatment.
Primary Outcome
We will measure the weeks required to reach treatment response defined as HDSS of 1 or 2.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-08-20 |
| Est. Completion | 2019-12-01 |
What the finished NCT03694093 record still lists
NCT03694093 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 41 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03694093 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03694093 about?
NCT03694093 is a clinical study titled "Assessing the Effect of Patient Characteristics on Treatment Response in Primary Hyperhidrosis". This study will describe the treatment of hyperhidrosis (excessive sweating) in clinical practice and explore the effect of patient characteristics on treatment response. This study will follow 200 people with hyperhidrosis over 18 months. Anyone with primary hyperhidrosis (excessive sweating not du...
What is the current status of trial NCT03694093?
This trial is currently completed. The enrollment target is 41 participants. The study started on 2018-08-20. Estimated completion is 2019-12-01.
Who is sponsoring clinical trial NCT03694093?
This trial is sponsored by St. Louis University, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI